CytomX Therapeutics (CTMX) Stock Rating Upgraded by BidaskClub
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.
A number of other brokerages have also weighed in on CTMX. Cowen reaffirmed an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Monday, October 16th. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, Oppenheimer reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $31.88.
CytomX Therapeutics (NASDAQ CTMX) opened at $21.66 on Friday. CytomX Therapeutics has a twelve month low of $10.40 and a twelve month high of $24.67.
A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. Numeric Investors LLC purchased a new stake in CytomX Therapeutics during the second quarter worth $9,730,000. State Street Corp boosted its position in CytomX Therapeutics by 58.8% during the second quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock worth $6,914,000 after purchasing an additional 165,342 shares in the last quarter. OxFORD Asset Management LLP boosted its position in CytomX Therapeutics by 425.6% during the third quarter. OxFORD Asset Management LLP now owns 166,079 shares of the biotechnology company’s stock worth $3,001,000 after purchasing an additional 134,484 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of CytomX Therapeutics by 1,063.5% in the second quarter. Goldman Sachs Group Inc. now owns 127,776 shares of the biotechnology company’s stock valued at $1,980,000 after acquiring an additional 116,794 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of CytomX Therapeutics by 185.3% in the third quarter. American Century Companies Inc. now owns 169,799 shares of the biotechnology company’s stock valued at $3,085,000 after acquiring an additional 110,283 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.